ELVN
Enliven Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.81B
P/E Ratio
—
EPS
$-1.64
Beta
0.40
52W High
$48.53
52W Low
$14.79
50-Day MA
$41.53
200-Day MA
$27.77
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Enliven Therapeutics Inc.
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer treatment and addressing critical health challenges through its proprietary therapeutic platforms. The company is advancing a diverse portfolio of drug candidates, leveraging cutting-edge biopharmaceutical technologies to enhance patient outcomes and elevate quality of life. With a steadfast commitment to scientific excellence and a strategic focus on fulfilling unmet medical needs in oncology, Enliven Therapeutics is poised to generate substantial shareholder value while making significant impacts within the healthcare sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-115.58M |
| Operating Margin | 0.00% |
| Return on Equity | -26.60% |
| Return on Assets | -18.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.45 |
| Price-to-Book | 6.20 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -6.28 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $60.91M |
| Float | $44.43M |
| % Insiders | 7.50% |
| % Institutions | 104.74% |
Historical Volatility
HV 10-Day
101.05%
HV 20-Day
78.67%
HV 30-Day
68.20%
HV 60-Day
74.01%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($60.11 target)
9
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026